Products
Industry-leading portfolio of water-free ophthalmic therapeutics
What is new about Novaliq’s products?
Novaliq develops first- and best-in-class ocular therapeutics based on EyeSol®, the worldwide first and only water-free technology, increasing residual time on the eye and enabling high bio-availability of active pharmaceutical ingredients (API) with excellent tolerability and safety with reduced extra-ocular systemic exposure. EyeSol® unlocks the full potential of APIs by generating novel drug products often with new Composition of Matter IP. The technology is clinically validated, safe and well accepted.
CyclASol®
ophthalmic solution of 0.1% cyclosporine A in EyeSol® developed to treat aqueous deficient DED
(investigational drug)
NOV03
first drug developed to treat evaporative DED associated with Meibomian gland dysfunction in a highly effective way
(investigational drug)
NovaTears®
First-in-class, preservation free eye treatment for tear film stabilization in dry eye.
(available in Europe, Australia and New Zealand)
NovaTears®+Omega-3
First-in-class, preservative-free and clear eye drop containing 0.2% Omega-3 fatty esters.
(coming soon)
What are the benefits of Novaliq’s products?
Clearly differentiated products based on our water-free EyeSol® platform. The key benefits are:
- Excellent suspendability and solubility of poorly soluble drugs
- Strong stability enhancement of antibodies, proteins and small molecules
- Optimal spreading and wetting abilities
- Strongly enhanced penetration
- Excellent safety and tolerability profile
- No preservatives
For which indications are products in development?
Dry Eye Disease (DED), Glaucoma and Retinal Diseases.
What products are next in the pipeline?
- CyclASol® – a preservative-free, clear cyclosporine A formulation in Phase II, for the treatment of moderate to severe DED.
- NovaTears®+Omega-3 – a first-in-class, preservative-free and clear eye drop containing 0,2% Omega-3. It stabilizes the lipid layer and reduces the evaporation of the underlying water phase of the tear film.
What clinical trials are currently under way?
- CyclASol® – a preservative-free, clear cyclosporine A formulation in Phase II for the treatment of moderate to severe DED (CYS-002).
- NovaTears® – a first-in-class, preservative free ophthalmic artificial tear for patients with mild to moderate dry eye disease (NT-004).
- NOV03 – a first-in-class, preservative free drug treatment addressing MGD and evaporative-caused DED (SEECASE-trial).
What are Novaliq’s products?
Novaliq offers an industry-leading portfolio of new, water-free and IP-protected ophthalmic therapeutics with proven market and clinical success.